[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Karplus G, Krasin MJ, Rodriguez-Galindo C, McCarville B, Jenkins J, Rao B, Spyridis G, Spunt SL: Retrospective study of the surgical management and outcome of nonrhabdomyosarcoma soft tissue sarcomas of the groin and axilla in children. J Pediatr Surg; 2009 Oct;44(10):1972-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of the surgical management and outcome of nonrhabdomyosarcoma soft tissue sarcomas of the groin and axilla in children.
  • PURPOSE: The incidence of pediatric nonrhabdomyosarcoma soft tissue sarcomas (NRSTSs) of the groin and axilla is unknown, and the optimal surgical approach to these patients is unclear.
  • METHODS: We conducted a retrospective study of patients treated at St Jude Children's Research Hospital from January 1962 to March 2007 for NRSTSs of the groin and axilla.
  • RESULTS: Of the 300 patients treated for NRSTSs, only 10 had tumors of the axilla or groin (6 of whom had synovial sarcoma).
  • Six patients underwent lymph node sampling; all were negative for tumor.
  • Four patients received adjuvant chemotherapy (n = 3) and/or radiotherapy (n = 2).
  • Two of these patients died of tumor progression (1 with metastases at diagnosis and 1 with an unresectable tumor at diagnosis), and one patient who was free of NRSTS died of secondary breast carcinoma.
  • CONCLUSIONS: Pediatric NRSTSs of the axilla and groin are rare, but outcomes are similar to those of other patients with NRSTS.
  • Wide local excision of the tumor with preservation of good limb function should be the surgical goal and may be sufficient therapy in some cases.
  • [MeSH-major] Axilla / surgery. Groin / surgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Cause of Death. Child. Female. Humans. Longitudinal Studies. Male. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Retrospective Studies. Rhabdomyosarcoma / surgery. Risk Factors. Sarcoma, Synovial / surgery. Soft Tissue Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4031-8 [15767644.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):852-9 [16199316.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):2006-12 [16161038.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1958-9; author reply 1959-60 [16622276.001]
  • [Cites] Future Oncol. 2006 Oct;2(5):667-73 [17026458.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1460-9 [17394945.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1202-9 [18440800.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1219 [10561182.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3697-705 [10577841.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1235-7 [11230463.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3225-35 [12149295.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):72-7 [8424704.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:117-9 [9057600.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):201-9 [9473754.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):76-82 [10398180.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3252-9 [10506627.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4021-30 [15767645.001]
  • (PMID = 19853757.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS502476; NLM/ PMC3748624
  •  go-up   go-down


2. Hamid AR, Umbas R: Metastasis of testicular carcinoma in the inguinal region. Acta Med Indones; 2009 Jan;41(1):25-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of testicular carcinoma in the inguinal region.
  • A standard protocol for the management of inguinal metastasis from testicular cancer still has not yet been established.
  • Metastasis of testicular cancer to inguinal lymph node rarely occurs, particularly in patients without any prior surgery in inguinal and scrotal region.
  • Daugaard reported 2% incidence of inguinal metastasis for stage 1 testicular cancer in 5-year period.
  • We reported a case of inguinal metastasis from residual testicular cancer with a large size of mass.
  • For this case, surgical treatment of residual tumor excision had been performed prior to the chemotherapy considering a quite large size of tumor mass, which may easily bleed and causing anemia to the patient.
  • Furthermore, we considered that chemotherapy treatment prior to surgical excision will only provide partial effect on the tumor.
  • After the surgery, a 4-cycle combined chemotherapy was administered despite the delay of chemotherapy treatment resulting in residual mass in inguinal region.
  • In fact, the post-surgical chemotherapy treatment in this case has demonstrated relatively good response.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Groin. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasm, Residual. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258677.001).
  • [ISSN] 0125-9326
  • [Journal-full-title] Acta medica Indonesiana
  • [ISO-abbreviation] Acta Med Indones
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Indonesia
  •  go-up   go-down


3. Bellati F, Angioli R, Manci N, Angelo Zullo M, Muzii L, Plotti F, Basile S, Panici PB: Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol; 2005 Jan;96(1):227-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases.
  • OBJECTIVE: The aim of this study was to evaluate acute and long-term morbidity, recurrence rate, and overall survival in patients with multiple groin lymph node metastases treated with postoperative chemotherapy.
  • METHODS: Patients affected by FIGO stages III, IVA, and IVB (pelvic lymph nodes only) submitted to surgery were then treated with four cycles of cisplatin 100 mg/m(2) given 21 days apart.
  • All patients completed the treatment.
  • No treatment-related deaths occurred.
  • Only two patients suffered from grade 4 neutropenia during chemotherapy.
  • CONCLUSIONS: In patients affected by vulvar cancer with multiple lymph node metastases, radical surgery followed by chemotherapy is a feasible strategy, with an acceptable short- and long-term complication rate.
  • Furthermore, due to absence of local long-term tissue toxicity, this strategy allows physicians to surgically treat regional lymph node recurrence safely.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Cisplatin / therapeutic use. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589606.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kretschmer L, Neumann C, Preusser KP, Marsch WC: Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. Acta Oncol; 2001;40(1):72-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence.
  • The present study addresses the question whether an extended ilioinguinal dissection as compared to an only superficial inguinal dissection improves survival and/or local tumour control after the appearance of palpable melanoma metastases to the groin.
  • We retrospectively analysed the data of 104 patients with 69 ilioinguinal and 35 superficial inguinal dissections (median follow up 127 months).
  • Prognostic factors of survival and groin recurrence were assessed using Kaplan-Meier estimation and Cox proportional hazards model.
  • By multifactorial analysis, metastatic involvement of two lymph nodes or less was associated with a significantly better survival rate than involvement of > 2 or pelvic nodes (p = 0.0002).
  • The probability of recurrence in the dissected groin paralleled the number of positive nodes and significantly increased if intransits were observed (p = 0.0002).
  • The extent of surgery, Breslow thickness, epidermal ulceration, sex, age and adjuvant chemotherapy neither significantly influenced survival nor local control rates.
  • In summary, when metastatic inguinal nodes become palpable, the presence of pelvic metastases indicates systemic disease.
  • After therapeutic groin dissection, local recurrence and survival depend rather on regional tumour burden than on the extent of surgery.
  • [MeSH-major] Lymph Node Excision. Melanoma / mortality. Melanoma / surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Groin / surgery. Humans. Inguinal Canal / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Survivors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321665.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


5. Duprat JP, Domingues AL, Coelho EG, Leal RM, Nishinari K, Neves RI: Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. Eur J Surg Oncol; 2009 Jun;35(6):568-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma.
  • INTRODUCTION: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm.
  • Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease.
  • Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Merkel Cell / drug therapy. Melphalan / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Chemotherapy, Cancer, Regional Perfusion. Extremities. Fatal Outcome. Female. Groin. Humans. Hyperthermia, Induced. Lymph Node Excision. Lymphatic Metastasis. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013049.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Number-of-references] 26
  •  go-up   go-down


6. Kilçiksiz S, Gökçe T, Kinay M: Isolated inguinal lymph node metastasis from breast carcinoma--case report and review of the literature. J BUON; 2006 Apr-Jun;11(2):229-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated inguinal lymph node metastasis from breast carcinoma--case report and review of the literature.
  • We report on a case of a premenopausal woman with breast cancer and unusual dissemination with isolated inguinal and iliac lymph node metastasis.
  • Painful edema developed at the right leg 69 months after the operation.
  • Diagnostic investigations revealed isolated right inguinal and iliac lymphadenopathy (LAP).
  • Four months later, abdominal magnetic resonance imaging (MRI) disclosed paraaortic and bilateral iliac and inguinal LAP.
  • Pathological assessment of the right inguinal LAP confirmed a metastasis from breast cancer.
  • After unsuccesful chemotherapy, palliative RT was performed to the inguinal, iliac and paraaortic lymph nodes, resulting in partial response.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Female. Groin. Humans. Lymphatic Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318976.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Rabbitt P, Pathma-Nathan N, Collinson T, Hewett P, Rieger N: Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal. ANZ J Surg; 2002 Sep;72(9):651-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal.
  • BACKGROUND: The current Trans-Tasman Radiation Oncology Group (TROG) protocol for T1 and T2 anal cancers is combination chemotherapy and radiotherapy excluding the inguinal region from the field.
  • Several centres worldwide irradiate both inguinal regions as there is a small incidence of involvement with early stage tumours.
  • The presence of inguinal lymph node metastases is not accurately detected using clinical and most radiological assessment modalities.
  • We have developed a method of sampling the sentinel node in the groin using established node mapping techniques.
  • METHODS: A combination of radio-labelled Antimony Sulphide and Patent Blue dye injected around the anal cancer enable identification of the sentinel node in the groin, using a gamma probe and direct visualization of the blue node.
  • A groin sentinel node was identified and removed in three of these, with pathological assessment excluding metastatic disease in the inguinal region.
  • The fourth patient had a sentinel node mapped to a meso-rectal node.
  • CONCLUSIONS: The application of this effective technique will allow accurate staging of anal cancers to better plan future treatment regimes.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Aged. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269917.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L: Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl); 2010 May;19(3):302-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Groin recurrence in carcinoma of the vulva: management and outcome.
  • The aim of the study was to investigate the management and outcome of inguinal recurrence in vulvar carcinoma patients.
  • Twenty-one patients were found to have groin recurrence.
  • Median interval between primary treatment of vulvar cancer and groin recurrence was 7 months.
  • Three patients refused any treatment, 3 received chemotherapy, 2 inguino-pelvic radiotherapy and 13 had resection of the groin recurrence.
  • After surgery seven patients received irradiation of the groin and pelvis, and three patients received chemotherapy.
  • One patient died following surgery; 19 patients died of disease with the median survival after diagnosis of inguinal recurrence of 9 months.
  • In univariate analysis, stage and grade at diagnosis, age and performance status at the recurrent disease, and the extent of residual tumour after resection of groin recurrence were predictors for survival.
  • Groin recurrences from vulvar carcinoma carry a poor prognosis.
  • Multi-modal treatment may result in a palliation of the disease, and a very limited number of patients have long-term survival.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Groin. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832900.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Otto T, Suhr J, Krege S, Rübben H: [Therapy of advanced penis carcinoma]. Urologe A; 2003 Nov;42(11):1466-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of advanced penis carcinoma].
  • [Transliterated title] Die Therapie des fortgeschrittenen Peniskarzinoms.
  • Skin infiltration and locoregional lymph node extension in metastatic penile cancer leads to destruction in the inguinal and perineal region.
  • The obligatorily superinfected defects require tension-free and extended coverage with immediate myocutaneous flaps after surgical resection.
  • Data concerning a prospective study for neoadjuvant chemotherapy with CMB followed by surgical tumor resection with immediate myocutaneous flap reconstruction are presented.
  • In 15 patients (median age: 69.7 years) suffering from squamous cell carcinoma of the penis (Tx, N3, M1 cutis), a surgical excision of the tumor was performed after neoadjuvant chemotherapy (median:2.4 cycles) and antibiotic pretreatment.
  • An extended (up to 45x30 cm) tension-free coverage of groin defects was performed in two patients with a unilateral M. tensor fasciae latae flap (TFL) and in eight patients with a bilateral TFL.
  • Of 31 myocutaneous pedicle flaps, 2 developed distant necrosis of the flap, in which one GMFL and one TFL were affected.
  • The covering of groin defects by the use of myocutaneous flaps, such as the M. tensor fasciae latae, M. rectus abdominis, and M. gluteus maximus flap, is a method of first choice in the primary treatment of even bacterially contaminated wounds or after radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoadjuvant Therapy. Penile Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotic Prophylaxis. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Graft Survival / drug effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Microsurgery. Neoplasm Invasiveness. Neoplasm Staging. Skin / pathology. Superinfection / prevention & control. Surgical Flaps / blood supply. Surgical Wound Infection / prevention & control. Suture Techniques. Treatment Outcome. Wound Healing / drug effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):1998-2005 [11743391.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):485-7 [3676574.001]
  • [Cites] Urologe A. 1997 Mar;36(2):157-61 [9199044.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] J Urol. 1982 Sep;128(3):599-601 [7120574.001]
  • [Cites] Urol Int. 1998;61(4):243-6 [10364759.001]
  • [Cites] Br J Plast Surg. 1982 Oct;35(4):413-9 [7139168.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):333-8 [1374199.001]
  • [Cites] J Urol. 2001 Oct;166(4):1384-5 [11547082.001]
  • [Cites] J Urol. 2003 Jan;169(1):118-20 [12478117.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1983 Jul;74(7):1113-21 [6663941.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):769-76 [9453463.001]
  • (PMID = 14624345.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, Averette HE: Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys; 2000 Nov 1;48(4):1007-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
  • PURPOSE: To determine if patients with carcinoma of the vulva, with N2/N3 lymph nodes, could undergo resection of the lymph nodes and primary tumor following preoperative chemo-radiation.
  • Patients underwent a split course of radiation, 4760 cGy to the primary and lymph nodes, with concurrent chemotherapy, cisplatin/5-FU, followed by surgery.
  • RESULTS: Four patients did not complete the chemo-radiation, because three expired and one refused to complete the treatment.
  • Four patients who completed chemo-radiation did not undergo surgery, because two of them died of non-cancer-related causes, and in the other two patients, the nodes remained unresectable.
  • Following chemo-radiation, the disease in the lymph nodes became resectable in 38/40 patients.
  • One underwent radical vulvectomy and unilateral node dissection and the other radical vulvectomy only.
  • The specimen of the lymph nodes was histologically negative in 15/37 patients.
  • Nineteen patients developed recurrent and/or metastatic disease.
  • The sites of failure were as follows: primary area only, 9; lymph node area only, 1; primary area and distant metastasis, 1; distant metastasis only, 8.
  • Local control of the disease in the lymph nodes was achieved in 36/37 and in the primary area in 29/38 of the patients.
  • Two patients died of treatment-related complications.
  • CONCLUSION: High resectability and local control rates of the lymph nodes were obtained in patients with carcinoma of the vulva with N2/N3 nodes treated preoperatively with chemo-radiation.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Lymph Node Excision. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Groin. Humans. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Treatment Failure

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11072157.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA27469
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Huang GS, Juretzka M, Ciaravino G, Kohler S, Teng NN: Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol Oncol; 2002 Dec;87(3):313-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma.
  • BACKGROUND: Primaryadenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established.
  • CASE: A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease.
  • Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection.
  • She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions.
  • Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life.
  • She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis.
  • CONCLUSIONS: We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Doxorubicin / therapeutic use. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Metastasis. Paget Disease, Extramammary / complications

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468332.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


12. Zangana AM, Razak AB: A giant testicular teratoma. Saudi Med J; 2007 Mar;28(3):465-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was invading the penis and lower part of abdominal wall including bilateral groin lymph nodes.
  • Radical excisions of the tumor including the shaft of the penis, combined with bilateral block dissection of the inguinal nodes and resection of the lower anterior abdominal wall was performed.
  • Six weeks later after a course of chemotherapy and radiotherapy, the patient underwent resection of metastatic lung lesion.
  • [MeSH-major] Lung Neoplasms / secondary. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Penile Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Iraq. Lymph Node Excision. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334483.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


13. Lamoreaux WT, Grigsby PW, Dehdashti F, Zoberi I, Powell MA, Gibb RK, Rader JS, Mutch DG, Siegel BA: FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):733-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare the results of CT and positron emission tomography (PET) and F-18 fluorodeoxyglucose (FDG) in the detection of the primary tumor and lymph node metastases in carcinoma of the vagina.
  • The primary tumor ranged in size from 2 to 10 cm (mean 4.9), and 4 patients had palpable groin lymph nodes.
  • All patients were treated with external beam radiotherapy and brachytherapy, 14 received concurrent chemotherapy, and 2 underwent primary tumor excision before the imaging evaluation.
  • CT also demonstrated abnormally enlarged groin lymph nodes in 3 patients and both groin and pelvic lymph nodes in 1 patient (4 of 23, 17%).
  • Abnormal uptake was found in the groin lymph nodes in 4 patients, pelvic lymph nodes in 2, and both groin and pelvic lymph nodes in 2 patients (8 of 23, 35%).
  • CONCLUSION: The results of this study have demonstrated that FDG-PET detects the primary tumor and abnormal lymph nodes more often than does CT.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Neoplasm Staging. Positron-Emission Tomography. Prospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936553.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Bafna UD, Devi UM, Naik KA, Hazra S, Sushma N, Babu N: Carcinoma of the vulva: a retrospective review of 37 cases at a regional cancer centre in South India. J Obstet Gynaecol; 2004 Jun;24(4):403-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical treatment consisted of wide excision in one case, radical vulvectomy (RV) in six cases, radical vulvectomy and bilateral groin node dissection (RV+BGND) in 25 cases and radical vulvectomy and unilateral groin node dissection in one case.
  • Nine of these 33 women also received adjuvant chemotherapy preoperatively in the hope of achieving better tumour-free surgical margins.
  • Overall, 26/33 cases had groin/inguinal node dissection and 23 (88.4%) of them had groin wound dehiscence.
  • Thirteen of these 26 patients (50%) had inguinal node metastases (Stage III, four patients; Stage IV, nine patients).
  • All the patients with negative nodes were free of disease while three of four patients with Stage III and two of nine patients with Stage IV with nodal metastases remained free of disease.
  • The only patient with Stage III disease plus inguinal node metastases who recurred had multiple positive nodes with extracapsular spread.
  • It appears that although bilateral involvement of the inguinal lymph nodes carries a worse prognosis, unilateral involvement with or without vaginal involvement carries an excellent prognosis provided multiple nodes are not involved.
  • The role of neoadjuvant chemotherapy as compared to neoadjuvant radiotherapy, in locally advanced tumours, needs to be explored further.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. India / epidemiology. Lymphatic Metastasis. Medical Records. Medically Underserved Area. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Regional Medical Programs. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15203581.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Frumovitz M, Ramirez PT, Tortolero-Luna G, Malpica A, Eifel P, Burke TW, Levenback C: Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecol Oncol; 2004 Jan;92(1):205-10
Hazardous Substances Data Bank. Isosulfan blue .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate patients with vulvar cancer who experienced a recurrence after undergoing lymphatic mapping and sentinel lymph node (SLN) biopsy.
  • METHODS: We reviewed the records of 52 patients who underwent vulvectomy and lymphatic mapping with blue dye for treatment of vulvar cancer at our institution from 1993 to 1999 and identified patients who experienced recurrent disease.
  • Thirteen patients underwent superficial inguinal lymphadenectomy while one patient underwent SLN biopsy only.
  • Postoperatively, seven patients underwent no further treatment, six underwent radiation therapy, and one patient underwent chemotherapy.
  • Primary recurrence was in the vulva in eight patients (57%), in the groin in three patients (21%), and distant in three patients (21%).
  • Of the three patients who experienced a recurrence in the groin, one had a negative SLN and negative non-SLN, one had a positive SLN and positive non-SLN, and one had no SLN identified and a negative non-SLN.
  • Groin relapse following a negative SLN biopsy is of concern and suggests that long-term follow-up data are required before lymphatic mapping and SLN biopsy alone can be considered standard treatment for patients with vulvar cancer.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy / methods. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Middle Aged. Retrospective Studies. Rosaniline Dyes

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751159.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue
  •  go-up   go-down


16. Barton DP: The prevention and management of treatment related morbidity in vulval cancer. Best Pract Res Clin Obstet Gynaecol; 2003 Aug;17(4):683-701
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevention and management of treatment related morbidity in vulval cancer.
  • The traditional and the most common management of primary vulval cancer is radical surgery of the vulva and radical groin lymphadenectomy (unilateral or bilateral).
  • Rare vulval cancers, locally advanced cancers and recurrent vulval cancers often are treated with a combination of surgery, radiation therapy and chemotherapy.
  • The treatments, while often curative, are associated with considerable morbidity, which, until recently, has not been well publicized or quantified.
  • Long-term post-treatment physical, sexual and psychological morbidity is of major concern.
  • There is more onus on clinicians to provide less radical but equally curative treatment, while also reducing morbidity.
  • There is also the need to provide treatment and treatment modification based on supporting evidence.
  • For a rare disease such as vulval cancer it is more difficult to generate data and to conduct trials on treatment modifications.
  • The prevention and management of treatment-related morbidity will continue to challenge the gynaecological oncology team.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Inguinal Canal. Lymph Node Excision. Lymphedema / therapy. Middle Aged. Morbidity. Patient Education as Topic. Quality of Life. Sexual Dysfunctions, Psychological / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12965139.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


17. Balogun TM, Omodele FO, Olaiya MA: Primary lymphoma of the testis in remission for more than ten years: a case report. West Afr J Med; 2009 Nov-Dec;28(6):388-90
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the most common testicular tumour in males between 60 and 80 years old OBJECTIVE: To report a case of primary testicular lymphoma in a young man who has done very well on surgery and chemotherapy.
  • METHODS: The patient a Nigerian male civil servant who was single and aged 31 years presented to us with a history of a progressive painful right scrotal swelling of two years duration and associated painful right groin swelling for one year.
  • A working diagnosis of right hydrocele with differential diagnosis of lymphangioma was made.
  • Right radical inguinal orchidectomy with excision of the right spermatic cord and a regional lymph node was carried out.
  • He was treated with systemic combination chemotherapy and has since been in complete remission for over 10 years.
  • CONCLUSION: Primary testicular lymphoma is a rare and unique neoplasm of the testis and is most commonly seen in men over the age of 60, but should be considered in the differential diagnosis of testicular tumours in younger age groups.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Orchiectomy. Remission Induction. Spermatic Cord / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486099.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


18. González-Bugatto F, Añón-Requena MJ, López-Guerrero MA, Báez-Perea JM, Bartha JL, Hervías-Vivancos B: Vulvar leiomyosarcoma in Bartholin's gland area: a case report and literature review. Arch Gynecol Obstet; 2009 Feb;279(2):171-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for vulvar leiomyosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumours of the vulvar soft tissue are very uncommon.
  • When localized in the Bartholin's gland area these tumours can be mistaken for benign lesions, leading to a delayed diagnosis.
  • Pathologist report informed of a 6 cm diameter leiomyosarcoma of the vulva with compromised resection margins; extension studies did not suggest any additional lesions and radical hemivulvectomy with ipsilateral inguinal lymphadenectomy was performed.
  • The patient subsequently received radiotherapy and chemotherapy.
  • This is particularly important in order to perform an effective surgical treatment in cases of leiomyosarcoma.
  • [MeSH-major] Bartholin's Glands / pathology. Leiomyosarcoma / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Groin. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437406.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 14
  •  go-up   go-down


19. Grundmann JU, Weisshaar E, Franke I, Bonnekoh B, Gollnick H: Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome. Int J Dermatol; 2003 Jun;42(6):461-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 32-year-old man was admitted to the Magdeburg University Hospital with icterus and for further diagnosis of suspected hepatitis.
  • The patient's history revealed the excision of a lymph node metastasis of the left groin showing pleomorphic macrocellular infiltrates, 2 months previously.
  • Further investigations revealed icterus of the sclera and multiple, firm tumors, which were located in the deep subcutaneous tissue, on the left hip, thigh, and buttock.
  • Chemotherapy could not be continued because of a Karnowsky index below 20%.
  • [MeSH-major] Keratoderma, Palmoplantar / genetics. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Drug Therapy, Combination. Fatal Outcome. Fluorouracil / therapeutic use. Humans. Male. Mitomycin / therapeutic use. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Evans Syndrome.
  • Genetic Alliance. consumer health - Howel-Evans syndrome.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12786874.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Vorob'ëv GI, Odariuk TS, Orlova LP, Nechushkin MI, Rybakov EG: [Prognosis of epidermoid anal carcinoma regression after conservative treatment]. Vopr Onkol; 2004;50(6):663-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of epidermoid anal carcinoma regression after conservative treatment].
  • The prospective study was concerned with definition of the clinical and therapeutic factors behind poor response of anal cancer to radio- (RT) or chemoradiotherapy (CRT).
  • Out of 64 female and 8 male patients at the mean age of 57 (33-81), thirty six had split-course of 60-65 Gy (RT), twenty--60-65 Gy, 5-FU and mitomycin C (CRT) and eighteen--up to 55-65 Gy (1.5 Gy--session 1, 1.0 Gy--session 2) (hyper-fractionated RT) plus 5-FU, for squamous cell anal carcinoma.
  • There was no endorectal ultrasound evidence of perirectal lymph node involvement (uN0): T1-2uN-M0 (n=46), T3-4uN0M0 (n=11), uN1 or N2-3 (groin or endorectal ultrasound: T1-2uN-M0 (n=46), T3-4uN0M0 (n=11), uN1 or N2-3 (groin metastases) were detected in 7 patients: T1-2uN1-2M0 (n=7), T3-4N1-3M0 (n=10).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Logistic Models. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755059.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement